Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

Authors Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W

Received 18 October 2012

Accepted for publication 26 November 2012

Published 23 January 2013 Volume 2013:9 Pages 21—28

DOI https://doi.org/10.2147/VHRM.S39300

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Valentina Lukashevich,1 Anja Schweizer,2 James E Foley,1 Sheila Dickinson,2 Per-Henrik Groop,3 Wolfgang Kothny1

1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Finland, and Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

Background: The purpose of this study was to evaluate the efficacy of vildagliptin 50 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m2) and longstanding type 2 diabetes not adequately controlled with insulin therapy, which is a difficult-to-treat population, with limited therapeutic options and a high susceptibility to hypoglycemia.
Methods: This was a post hoc subanalysis of data obtained during a previously described randomized, double-blind, parallel-group, 24-week study comparing the efficacy and safety of vildagliptin 50 mg once daily versus placebo in patients with type 2 diabetes and moderate or severe renal impairment. The present data derive from 178 patients with severe renal impairment (baseline estimated glomerular filtration rate approximately 21 mL/min/1.73 m2, 100 randomized to vildagliptin, 78 randomized to placebo), all of whom were receiving insulin therapy (alone or in combination with an oral antidiabetic agent) for longstanding type 2 diabetes (mean approximately 19 years).
Results: With vildagliptin in combination with insulin, the adjusted mean change (AMΔ) in HbA1c from baseline (7.7% ± 0.1%) was -0.9% ± 0.4% and the between-treatment difference (vildagliptin – placebo) was -0.6% ± 0.2% (P < 0.001). The percentage of patients achieving endpoint HbA1c < 7.0% was significantly higher with vildagliptin than placebo (45.2% versus 22.8%, P = 0.008). When added to insulin, vildagliptin and placebo had comparable hypoglycemic profiles and did not cause weight gain. Both treatments were similarly well tolerated, with comparable incidences of adverse events, serious adverse events, and deaths.
Conclusion: When added to insulin therapy in patients with severe renal impairment and longstanding type 2 diabetes, vildagliptin 50 mg once daily was efficacious, eliciting HbA1c reductions consistent with those previously reported for a patient population with much more recent onset of type 2 diabetes and normal renal function, and had a hypoglycemic profile comparable with placebo. Accordingly, vildagliptin is a suitable treatment option for patients with advanced type 2 diabetes and impaired renal function who require insulin therapy and present a serious therapeutic challenge in clinical practice.

Keywords: chronic kidney disease, antidiabetic drug, dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1, type 2 diabetes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Thoracoabdominal aortic aneurysm repair: current endovascular perspectives

Orr N, Minion D, Bobadilla JL

Vascular Health and Risk Management 2014, 10:493-505

Published Date: 19 August 2014

How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study

Penfornis A, Blicklé JF, Fiquet B, Quéré S, Dejager S

Vascular Health and Risk Management 2014, 10:341-352

Published Date: 13 June 2014

Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension

Litvin AY, Sukmarova ZN, Elfimova EM, Aksenova AV, Galitsin PV, Rogoza AN, Chazova IE

Vascular Health and Risk Management 2013, 9:229-235

Published Date: 10 May 2013

Endoglin: a critical mediator of cardiovascular health

Kapur NK, Morine KJ, Letarte M

Vascular Health and Risk Management 2013, 9:195-206

Published Date: 6 May 2013

Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry

Schaefer JR, Gitt AK, Sonntag F, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K

Vascular Health and Risk Management 2013, 9:71-80

Published Date: 21 February 2013

Everolimus-eluting stents in interventional cardiology

Townsend JC, Rideout P, Steinberg DH

Vascular Health and Risk Management 2012, 8:393-405

Published Date: 27 June 2012

Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection

Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al

Vascular Health and Risk Management 2010, 6:479-494

Published Date: 22 June 2010